# Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

> **NCT05033769** · PHASE4 · UNKNOWN · sponsor: **Institut fuer Frauengesundheit** · enrollment: 82 (estimated)

## Conditions studied

- Breast Cancer Female
- Neoplasm, Breast
- Breast Cancer Metastatic

## Interventions

- **DRUG:** Eribulin Injection [Halaven]
- **DRUG:** Paclitaxel injection

## Key facts

- **NCT ID:** NCT05033769
- **Lead sponsor:** Institut fuer Frauengesundheit
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-11
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-09-15
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05033769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05033769, "Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05033769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*